| アブストラクト | Pre-clinical evidence suggests that 5-alpha reductase inhibitors (5ARi's), prescribed in the treatment of benign prostatic hyperplasia, reduce colorectal and gastro-oesophageal cancer incidence via action on the male hormonal pathway. However, few studies to date have investigated this association at the population level. Our study aimed to investigate the risk of colorectal and gastro-oesophageal cancers with the use of 5ARi's. We conducted a retrospective cohort study of new users of 5ARi's and alpha-blockers among patients with benign prostatic hyperplasia in the UK Clinical Practice Research Datalink. Patients were followed until a first ever diagnosis of colorectal or gastro-oesophageal cancer, death from any cause or end of registration with the general practice or 31st of December 2017. Cox proportional hazards models with inverse probability of treatment weights were used to calculate weighted hazard ratios (HR) and 95% confidence intervals (CIs) of incident colorectal cancer or gastro-oesophageal cancer associated with the use of 5ARi's compared to alpha-blockers. During a mean follow-up of 6.6 years, we found no association between the use of 5ARi's and colorectal (HR: 1.13, 95% CI 0.91-1.41) or gastro-oesophageal (HR 1.14, 95% CI 0.76-1.63) cancer risk compared to alpha-blockers. Sensitivity analysis showed largely consistent results when varying lag periods, using multiple imputations, and accounting for competing risk of death. Our study found no association between the use of 5ARi's and risk of colorectal or gastro-oesophageal cancer in men with benign prostatic hyperplasia. |
|---|
| ジャーナル名 | International journal of cancer |
|---|
| 投稿日 | 2024/3/30 |
|---|
| 投稿者 | Doherty, Niamh; Cardwell, Chris; Murchie, Peter; Hill, Christopher; Azoulay, Laurent; Hicks, Blanaid |
|---|
| 組織名 | Centre for Public Health, Queen's University Belfast, Belfast, UK.;School of Medicine, Medical Sciences and Nutrition, University of Aberdeen,;Aberdeen, UK.;Regional Nephrology Unit, Belfast City Hospital, Belfast, UK.;Centre for Clinical Epidemiology Lady Davis Institute, Jewish General Hospital,;Montreal, Qubec, Canada.;Department of Epidemiology, Biostatistics, and Occupational Health and Gerald;Bronfman Department of Oncology, McGill University, Montreal, Qubec, Canada. |
|---|
| Pubmed リンク | https://www.ncbi.nlm.nih.gov/pubmed/38554127/ |
|---|
